Recognition, Diagnosis, and Treatment of Histoplasmosis Complicating Tumor Necrosis Factor Blocker Therapy

Clinical Infectious Diseases ◽

10.1086/648724 ◽

2010 ◽

Vol 50 (1) ◽

pp. 85-92 ◽

Author(s):

Chadi A. Hage ◽

Suzanne Bowyer ◽

Stacey E. Tarvin ◽

Debra Helper ◽

Martin B. Kleiman ◽

...

Keyword(s):

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Diagnosis And Treatment ◽

Blocker Therapy ◽

Tumor Necrosis Factor Blocker ◽

Necrosis Factor

Download Full-text

Tumor necrosis factor–blocker therapy persistence, gaps, and switching among patients with psoriatic arthritis

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2011.11.861 ◽

2012 ◽

Vol 66 (4) ◽

pp. AB206

Keyword(s):

Psoriatic Arthritis ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Blocker Therapy ◽

Tumor Necrosis Factor Blocker ◽

Necrosis Factor

Download Full-text

P023 Disseminated Histoplasmosis in a Patient with Crohn's Disease Under Tumor Necrosis Factor Blocker Therapy: An Unusual Case

The American Journal of Gastroenterology ◽

10.14309/01.ajg.0000613060.27726.48 ◽

2019 ◽

Vol 114 (1) ◽

pp. S6-S7

Author(s):

Sandro Ferreira ◽

Fernando Jorge Nóbrega ◽

Roberta Araujo ◽

Rodrigo Santana ◽

Leandra Ramalho ◽

...

Keyword(s):

Crohn’S Disease ◽

Tumor Necrosis Factor ◽

Crohn's Disease ◽

Tumor Necrosis ◽

Unusual Case ◽

Blocker Therapy ◽

Tumor Necrosis Factor Blocker ◽

Disseminated Histoplasmosis ◽

Necrosis Factor

Download Full-text

Which treatments had been tapered or stopped in rheumatoid arthritis in long-term DAS28 remission following subcutaneous tumor-necrosis-factor blocker therapy? A retrospective experience on 43 patients

Joint Bone Spine ◽

10.1016/j.jbspin.2012.02.006 ◽

2012 ◽

Vol 79 (5) ◽

pp. 520-521

Author(s):

Sanae Ali Ou Alla ◽

Cedric Lukas ◽

Najia Hajjaj-Hassouni ◽

René Marc Flipo ◽

Bernard Combe ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Blocker Therapy ◽

Subcutaneous Tumor ◽

Tumor Necrosis Factor Blocker ◽

Das28 Remission ◽

Necrosis Factor

Download Full-text

National and regional dose escalation and cost of tumor necrosis factor blocker therapy in biologic-naïve rheumatoid arthritis patients in US health plans

Journal of Medical Economics ◽

10.3111/13696998.2013.856314 ◽

2013 ◽

Vol 17 (1) ◽

pp. 1-10 ◽

Author(s):

Amie T. Joyce ◽

Shravanthi R. Gandra ◽

Kathleen M. Fox ◽

Timothy W. Smith ◽

Michael W. Pill

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis Factor ◽

Dose Escalation ◽

Tumor Necrosis ◽

Health Plans ◽

Blocker Therapy ◽

Tumor Necrosis Factor Blocker ◽

Necrosis Factor

Download Full-text

PMS69 Tumor Necrosis Factor Blocker Dose Escalation among Biologic Naïve Rheumatoid Arthritis (RA) Patients in Commercial Managed Care Plans in the Two Years Following Therapy Initiation

Value in Health ◽

10.1016/j.jval.2012.03.258 ◽

2012 ◽

Vol 15 (4) ◽

pp. A46

Author(s):

M. Bonafede ◽

S.R. Gandra ◽

K.M. Fox ◽

K. Wilson

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis Factor ◽

Managed Care ◽

Dose Escalation ◽

Tumor Necrosis ◽

Tumor Necrosis Factor Blocker ◽

Therapy Initiation ◽

Necrosis Factor

Download Full-text

Using real-world drug utilization to estimate tumor necrosis factor blocker cost for treated psoriasis patients in a managed care setting

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2011.11.863 ◽

2012 ◽

Vol 66 (4) ◽

pp. AB206

Keyword(s):

Tumor Necrosis Factor ◽

Managed Care ◽

Drug Utilization ◽

Tumor Necrosis ◽

Care Setting ◽

Tumor Necrosis Factor Blocker ◽

Necrosis Factor

Download Full-text

SAT0143 Tumor necrosis factor-blocker use in us managed care: Utilization and dosing patterns among rheumatoid arthritis patients:

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2012-eular.3090 ◽

2013 ◽

Vol 71 (Suppl 3) ◽

pp. 520.1-520

Author(s):

M. Fisher ◽

C. Watson ◽

K.M. Fox ◽

Y.-W. Chen ◽

S.R. Gandra

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis Factor ◽

Managed Care ◽

Tumor Necrosis ◽

Care Utilization ◽

Tumor Necrosis Factor Blocker ◽

Necrosis Factor ◽

Dosing Patterns

Download Full-text

PMS16 Cost of Tumor Necrosis Factor Blocker Per Treated Psoriatic Arthritis Patient Using Drug Utilization Data from a US Managed Care Population

Value in Health ◽

10.1016/j.jval.2012.03.205 ◽

2012 ◽

Vol 15 (4) ◽

pp. A36

Author(s):

M. Bonafede ◽

C. Watson ◽

S.R. Gandra ◽

N. Princic ◽

K.M. Fox

Keyword(s):

Psoriatic Arthritis ◽

Tumor Necrosis Factor ◽

Managed Care ◽

Drug Utilization ◽

Tumor Necrosis ◽

Tumor Necrosis Factor Blocker ◽

Utilization Data ◽

Necrosis Factor

Download Full-text

Editorial review: how early should ankylosing spondylitis be treated with a tumor necrosis factor-blocker?

Current Opinion in Rheumatology ◽

10.1097/bor.0b013e32833aaf93 ◽

2010 ◽

Vol 22 (4) ◽

pp. 388-392 ◽

Author(s):

Hildrun Haibel ◽

Joachim Sieper

Keyword(s):

Ankylosing Spondylitis ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Tumor Necrosis Factor Blocker ◽

Editorial Review ◽

Necrosis Factor

Download Full-text

Radiographic progression in patients with ankylosing spondylitis according to tumor necrosis factor blocker exposure: Observation Study of Korean Spondyloarthropathy Registry (OSKAR) data

Joint Bone Spine ◽

10.1016/j.jbspin.2015.09.006 ◽

2016 ◽

Vol 83 (5) ◽

pp. 569-572 ◽

Author(s):

Tae-Jong Kim ◽

Ji-Hui Shin ◽

Suna Kim ◽

Il-Hoon Sung ◽

Seunghun Lee ◽

...

Keyword(s):

Ankylosing Spondylitis ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Radiographic Progression ◽

Observation Study ◽

Tumor Necrosis Factor Blocker ◽

Necrosis Factor

Download Full-text